Unity Biotechnology Inc. (UBX)
Unity Biotechnology Statistics
Share Statistics
Unity Biotechnology has 16.87M shares outstanding. The number of shares has increased by 0.46% in one year.
| Shares Outstanding | 16.87M |
| Shares Change (YoY) | 0.46% |
| Shares Change (QoQ) | 0.1% |
| Owned by Institutions (%) | 1.66% |
| Shares Floating | 15.38M |
| Failed to Deliver (FTD) Shares | 943 |
| FTD / Avg. Volume | 0.33% |
Short Selling Information
The latest short interest is 222.26K, so 1.32% of the outstanding shares have been sold short.
| Short Interest | 222.26K |
| Short % of Shares Out | 1.32% |
| Short % of Float | 1.45% |
| Short Ratio (days to cover) | 0.73 |
Valuation Ratios
The PE ratio is -0.63 and the forward PE ratio is -1.66. Unity Biotechnology's PEG ratio is 0.01.
| PE Ratio | -0.63 |
| Forward PE | -1.66 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 2.53 |
| P/FCF Ratio | -0.79 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Unity Biotechnology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.62, with a Debt / Equity ratio of 3.03.
| Current Ratio | 2.62 |
| Quick Ratio | 2.62 |
| Debt / Equity | 3.03 |
| Debt / EBITDA | -0.63 |
| Debt / FCF | -0.94 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.62M |
| Employee Count | 16 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -36.94% in the last 52 weeks. The beta is 1.3, so Unity Biotechnology's price volatility has been higher than the market average.
| Beta | 1.3 |
| 52-Week Price Change | -36.94% |
| 50-Day Moving Average | 1.8 |
| 200-Day Moving Average | 1.49 |
| Relative Strength Index (RSI) | 30.11 |
| Average Volume (20 Days) | 283.63K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -31.17M |
| Net Income | -25.99M |
| EBITDA | -31.17M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.54 |
Balance Sheet
The company has 7.58M in cash and 19.71M in debt, giving a net cash position of -12.13M.
| Cash & Cash Equivalents | 7.58M |
| Total Debt | 19.71M |
| Net Cash | -12.13M |
| Retained Earnings | -510.34M |
| Total Assets | 37.66M |
| Working Capital | 15.01M |
Cash Flow
In the last 12 months, operating cash flow was -20.86M and capital expenditures 0, giving a free cash flow of -20.86M.
| Operating Cash Flow | -20.86M |
| Capital Expenditures | 0 |
| Free Cash Flow | -20.86M |
| FCF Per Share | -1.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
UBX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for UBX is $4, which is 304% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 304% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Oct 20, 2022. It was a backward split with a ratio of 1:10.
| Last Split Date | Oct 20, 2022 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -20.91 |
| Piotroski F-Score | 1 |